You are here: Home » International » News » Companies
Business Standard

Eli Lilly to continue other Covid-19 antibody drug trials after pausing one

Lilly said the government-sponsored clinical trial of its Covid-19 antibody treatment, which is similar to one taken by U.S. President Donald Trump, had been paused over safety concerns.

Topics
Eli Lilly | Coronavirus Vaccine

Reuters 

Eli Lilly logo is shown on one of the company's offices in San Diego, California. Photo: Reuters
Eli Lilly logo is shown on one of the company's offices in San Diego, California. Photo: Reuters

& Co on Wednesday said that other trials of its experimental Covid-19 antibody drug will continue apace after it paused one ongoing trial of the drug, citing safety concerns.

The paused trial, which Lilly calls ACTIV-3, focused on hospitalized patients. Lilly said it differed from its other trials in some key respects, including the fact that the patients had more serious illness and were being treated with other drugs, including Gilead Sciences Inc’s remdesivir.

Lilly said in a statement that neutralizing antibody drugs such as bamlanivimab, which it is studying in Covid-19 patients, may be less beneficial for hospitalized patients than for those with more mild cases of the disease.

The trial was paused at the request of an oversight board, called a Data Safety and Monitoring Board (DSMB), that also reviews data on other U.S. government-backed studies of Covid-19 medicines. It is not uncommon to pause drug trials to investigate safety concerns, and such actions do not necessarily indicate a serious problem.

“Lilly trusts the judgment of the independent DSMB and supports its decisions to exercise caution in ensuring the safety of the patients participating in this study,” the company said in a statement.

Lilly said on Tuesday the government-sponsored clinical trial of its Covid-19 antibody treatment, which is similar to one taken by U.S. President Donald Trump, had been paused over safety concerns.

Lilly said earlier this month it was applying for emergency use authorization (EUA) for the antibody drug, also called LY-CoV555, for patients with mild to moderate Covid-19 based on data from another clinical trial. It is also testing the drug in nursing homes to see if it can prevent staff and residents from getting infected.

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Wed, October 14 2020. 20:30 IST
RECOMMENDED FOR YOU
.